Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29207353 | 0.92 | CYP1A2 (0.35) | CYP1A2CYP2A6AHR | |
| SCHEMBL10454827 | 0.77 | CYP2A6 (0.45) | CYP2A6 | |
| SCHEMBL1587165 | 0.76 | ALDH1A1 (0.35) | CYP1A2CYP2A6TSHRALDH1A1TDP1 | |
| SCHEMBL18242173 | 0.76 | — | — | |
| SCHEMBL6482087 | 0.75 | ALDH1A1 (0.36) | CYP1A2TSHRALDH1A1L3MBTL1 | |
| SCHEMBL4316327 | 0.73 | CYP2A6 (0.38) | CYP1A2CYP2A6AHRTSHRLMNA | |
| SCHEMBL22749322 | 0.73 | CYP2A6 (0.39) | CYP2A6 | |
| SCHEMBL1193110 | 0.71 | CYP2A6 (0.48) | CYP1A2CYP2A6LMNAKMT2A | |
| SCHEMBL456807 | 0.71 | BACE1 (0.33) | CYP2A6NOS1CA12CA9 | |
| SCHEMBL465027 | 0.71 | CYP1A2 (0.36) | CYP1A2CYP2A6TSHRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117983302-A | Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | claimed |
| CN-117983300-A | Catalyst containing N-triptycene ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | claimed |
| CN-116726998-A | Catalyst containing biphosphine ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2023-09-12 | — | — | CN | claimed |
| CN-115353506-A | 3-substituted phenanthridine compound, preparation method and application thereof, and pharmaceutical composition | 苏州施安鼎泰生物医药技术有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117983302-A | Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-117983300-A | Catalyst containing N-triptycene ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116726998-A | Catalyst containing biphosphine ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2023-09-12 | — | — | CN | disclosed |
| EP-4229053-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023125627-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| EP-0014402-B1 | NOVEL 20-0-ACYLMAYTANSINOIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Chemical Industries, Ltd. (JP) | 1983-07-20 | — | — | EP | disclosed |
| US-4361650-A | BACILLUS, STREPTOMYCES OR ACTINOMYCES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-11-30 | — | — | US | disclosed |
| EP-0004466-B1 | DEMETHYL MAYTANSINOIDS AND METHODS FOR PRODUCING THEM | Takeda Chemical Industries, Ltd. (JP) | 1982-01-27 | — | — | EP | disclosed |
| US-4307016-A | FUNGICIDES, PROTOZOACIDES OR ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-12-22 | — | — | US | disclosed |
| US-4263294-A | ANTITUMOUR AGENTS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-04-21 | — | — | US | disclosed |
| EP-0011302-A1 | Maytansinoids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1980-05-28 | — | — | EP | disclosed |
| EP-0004466-A1 | Demethyl maytansinoids and methods for producing them | Takeda Chemical Industries, Ltd. (JP) | 1979-10-03 | — | — | EP | disclosed |
| US-4139537-A | 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds | COOPER LABORATORIES, INC. (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4667/4885CYP2A6 3834/4885AHR 2218/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4667/4885CYP2A6 3834/4885AHR 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.